

REMARKS

The Response filed August 14, 2006 was returned for improperly listing the status of Claim 11 as both "original" and "canceled." The Applicants now resubmit the Response with Claim 11 properly identified as "canceled." In addition, the Applicants now cancel Claim 23 which was dependent upon non-elected Claim 4. The Applicants believe the Examiner's incorporation of Claim 23 into Group I was in error as it is directed toward methods of transplanting transplantable cells.

For the Examiner's convenience, the Restriction Requirement Response is provided below.

Claims 1-46 were originally filed in the present application. In the Restriction Requirement mailed July 10, 2006, the Examiner restricted Claims 1-46 into the following nine groups:

- I. Claims 1-3, 12, 13, 16-23, 34, 35, and 41-43; drawn to methods for obtaining stem cells from an umbilical cord matrix and cultured isolates comprising stem cells isolated from an umbilical cord matrix source of stem cells, methods of generating a bank of stem cells from an umbilical cord matrix;
- II. Claim 5, drawn to methods of differentiating stem cells to a transplantable cells to produce an ectodermal cell;
- III. Claim 6, drawn to methods of differentiating stem cells to a transplantable cells to produce an endodermal cell;
- IV. Claim 7, drawn to methods of differentiating stem cells to a transplantable cells to produce an neuroectodermal cell;
- V. Claim 8, drawn to methods of treating a mammalian subject for alleviation of a disease symptom using transformed cell comprising stem cells;
- VI. Claims 9-11, 15, drawn to methods of introducing a foreign gene into a stem cell;
- VII. Claims 24-28, and 36-40, drawn to methods of transplanting a neural transplantable cell into a patient;
- VIII. Claims 29-31, drawn to methods of inducing the production of myofibroblast cells and introducing said cells into a patient; and
- IX. Claims 44-46, drawn to methods of generating transgenic or chimeric animals, comprising injection of UCMS cells into morulae and/or blastocysts.


PATENT
Attorney Docket No. **KSURF-08401**

Restriction Requirement, pages 2-3. The Applicant herein elects, without traverse, to prosecute the claims of Group I. The Applicant also herein cancels Claims 4-11, 15, 23-31, 36-40 and 44-46 in order to further their business interests and the prosecution of the present application while preserving the right to prosecute the canceled (or similar) claims in the future. The Applicants note that Claims 14, 32 and 33 were not addressed in the Restriction Requirement.

CONCLUSION

As such, Claims 1-3, 12, 13, 14, 16-22, 32-35, and 41-43 are pending and under examination following entry of Applicant's response to the outstanding Restriction Requirement. Should the Examiner believe that a telephone interview would aid in the prosecution of this application Applicants encourage the Examiner to call the undersigned collect at (608) 218-6900.

Dated: 12-6-06



Robert A. Goetz
Registration No. 55,210

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608.218.6900